@article{f90f61305c4b41dca40e527a133b9d7f,
title = "A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.",
keywords = "ORAL ANTICOAGULANT-THERAPY, INTERNATIONAL NORMALIZED RATIO, WARFARIN THERAPY, BLEEDING COMPLICATIONS, ATRIAL-FIBRILLATION, CYTOCHROME P4502C9, ECONOMIC OUTCOMES, DOSE REQUIREMENT, CYP2C9, VKORC1",
author = "Verhoef, \{Talitha I\} and Redekop, \{William K\} and Josep Darba and Mary Geitona and Hughes, \{Dyfrig A\} and Uwe Siebert and \{de Boer\}, Anthonius and \{Maitland-van der Zee\}, Anke-Hilse and Rita Barallon and Montserrat Briz and Ann Daly and Elisabeth Haschke-Becher and Farhad Kamali and Julia Kirchheiner and Manolopoulos, \{Vangelis G\} and Munir Pirmohamed and Rosendaal, \{Frits R\} and \{van Schie\}, \{Rianne M F\} and Mia Wadelius",
year = "2010",
doi = "10.2217/pgs.10.74",
language = "English",
volume = "11",
pages = "989--1002",
journal = "PHARMACOGENOMICS",
issn = "1462-2416",
publisher = "Future Medicine ",
number = "7",
}